State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA

Author(s):  
Amin El-Heliebi ◽  
Ellen Heitzer
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Moses Effiong Ekpenyong ◽  
Mercy Ernest Edoho ◽  
Udoinyang Godwin Inyang ◽  
Faith-Michael Uzoka ◽  
Itemobong Samuel Ekaidem ◽  
...  

AbstractWhereas accelerated attention beclouded early stages of the coronavirus spread, knowledge of actual pathogenicity and origin of possible sub-strains remained unclear. By harvesting the Global initiative on Sharing All Influenza Data (GISAID) database (https://www.gisaid.org/), between December 2019 and January 15, 2021, a total of 8864 human SARS-CoV-2 complete genome sequences processed by gender, across 6 continents (88 countries) of the world, Antarctica exempt, were analyzed. We hypothesized that data speak for itself and can discern true and explainable patterns of the disease. Identical genome diversity and pattern correlates analysis performed using a hybrid of biotechnology and machine learning methods corroborate the emergence of inter- and intra- SARS-CoV-2 sub-strains transmission and sustain an increase in sub-strains within the various continents, with nucleotide mutations dynamically varying between individuals in close association with the virus as it adapts to its host/environment. Interestingly, some viral sub-strain patterns progressively transformed into new sub-strain clusters indicating varying amino acid, and strong nucleotide association derived from same lineage. A novel cognitive approach to knowledge mining helped the discovery of transmission routes and seamless contact tracing protocol. Our classification results were better than state-of-the-art methods, indicating a more robust system for predicting emerging or new viral sub-strain(s). The results therefore offer explanations for the growing concerns about the virus and its next wave(s). A future direction of this work is a defuzzification of confusable pattern clusters for precise intra-country SARS-CoV-2 sub-strains analytics.


2014 ◽  
Vol 3 (1) ◽  
Author(s):  
Shidong Jia ◽  
Winston Patrick Kuo

This editorial article introduces a renaming of journal Exosomes and Microvesicles (EXMV) to the Journal of Circulating Biomarkers with a new editorial scope, mission and our approach for the upcoming year in relation to engaging at the international level, the translational art of the study of exosomes and microvesicles, and the interface between exosomes and microvesicles, circulating tumor cells, cell-free circulating DNA and circulating protein markers in precision medicine and drug development. There is a slight change in the members of the Editors in Chief, Editorial Board and extending collaborations to international societies, such as the American Society for Exosomes and Microvesicles (ASEMV).


Author(s):  
Dmitry Evseev ◽  
Irina Kalinina ◽  
Elena Raykina ◽  
Daria Osipova ◽  
Zalina Abashidze ◽  
...  

Background Langerhans cell histiocytosis (LCH) involves abnormal proliferation of Langerhans cells (LC), which is typically driven by the BRAF V600E mutation. High-risk LCH has a poor prognosis. Procedure Fifteen children (5 girls, 10 boys) with BRAF V600E+ LCH received vemurafenib (initial dose median 40 mg/kg/day, range: 11–51.6 mg/kg/day) between March 2016 and February 2020. All patients had previous received LCH-directed chemotherapy. The median age at LCH onset was 2 months (range: 1–28 months) and the median age at the start of vemurafenib treatment was 22 months (range: 13–62 months). The median disease activity score (DAS) at the start of vemurafenib treatment was 12 points (range: 2–22 points). Results The median duration of vemurafenib therapy was 29 months (range: 2.4–45 months). All patients responded to treatment, with median DAS values of 4 points (range: 0–14 points) at week 4 and 1 point (range: 0–3 points) at week 26. Toxicities included skin/hair changes (93%) and non-significant QT prolongation (73%). Two patients died, including 1 patient who experienced hepatic failure after NSAID overdose and 1 patient who developed neutropenic sepsis. Electively stopping vemurafenib treatment resulted in relapse in 5 patients, and complete cessation was only possible for 1 patient. Digital droplet PCR for BRAF V600E using cell-free circulating DNA revealed that 7 patients had mutation statuses that fluctuated over time. Conclusion Our study confirms that vemurafenib treatment is safe and effective for young children with BRAF V600E+ multisystem LCH. However, treatment using vemurafenib does not completely eliminate the disease.


Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15266-15274 ◽  
Author(s):  
Asuka Morikawa ◽  
Tomoatsu Hayashi ◽  
Naomi Shimizu ◽  
Mana Kobayashi ◽  
Kenzui Taniue ◽  
...  

2018 ◽  
Vol 50 (5S) ◽  
pp. 3
Author(s):  
Nils Haller ◽  
Susanne Helmig ◽  
Pascal Taenny ◽  
Julian Petry ◽  
Sebastian Schmidt ◽  
...  

Author(s):  
Espen Oland ◽  
Rune Schlanbusch ◽  
Shaun Falconer

This paper presents a review of different condition monitoring technologies for fiber ropes. Specifically, it presents an overview of the articles and patents on the subject, ranging from the early 70’s up until today with the state of the art. Experimental results are also included and discussed in a conditionmonitoring context,where failuremechanisms and changes in physical parameters give improved insight into the degradation process of fiber ropes. From this review, it is found that automatic width measurement has received surprisingly little attention, and might be a future direction for the development of a continuous condition monitoring system for synthetic fiber ropes.


Sign in / Sign up

Export Citation Format

Share Document